Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Alexza Pharmaceuticals has launched ADASUVE inhalation powder, pre-dispensed (loxapine) in the Nordic countries including Sweden, Norway, Denmark and Finland.
Subscribe to our email newsletter
Grupo Ferrer Internacional (Ferrer) is commercializing ADASUVE in the Nordic countries via a distribution agreement with Medivir.
Ferrer is Alexza’s commercial partner for ADASUVE in the Europe, Latin America and the Commonwealth of Independent States countries.
Alexza president and CEO Thomas King said with the launch of ADASUVE in the Nordic Countries, Ferrer is continuing to execute on its planned commercial launch.
"We are very pleased with their progress in making ADASUVE available in the EU," King said.
"Manufacturing finished product for our commercial partners is one of Alexza’s key priorities and we continue to support the global introduction of ADASUVE."
In February 2013, Alexza secured marketing authorization for ADASUVE from the European Commission (EC).
The company said that ADASUVE is the first inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder authorized for marketing in the EU.
The marketing authorization for ADASUVE requires that patients receive regular treatment immediately after administration of the product to control acute agitation symptoms.